January 31, 2002
People were analyzed according to baseline CD4 cell count (below 200, 200 to 349, and 350 or more), and baseline viral load (below 10,000, 10,000 to 99,999, 100,000 or more). The authors analyzed the number of people who achieved a viral load below 500 after initiating therapy, and the number who had viral rebound to more than 500. There were no significant differences observed in the number of people achieving a viral load below 500, or in the number who had viral rebound based on the starting CD4 cell count or viral load. There were no differences observed based on gender. The only difference noted was that in the high viral load group, 100,000 or more, it took longer to achieve viral suppression. Overall, 85% of people achieved viral suppression. The death rate was higher in the people who started ART with a CD4 cell count below 200, but was not different in the other two groups, 200 to 349, and 350 or more.
The authors note that a retrospective cohort study such as this cannot definitively answer the question of when to start ART, but the data does help provide some guidance to clinicians and people with HIV. Also, they note that the low clinical events rate observed in this study "indicate[s] that a randomized trial of immediate vs. deferred therapy would likely have to be very large and last several years." This study does provide some data which questions the prevailing wisdom that it is easier to achieve durable virologic suppression if you begin ART at a higher CD4 cell count, or lower viral load.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.